Format

Send to

Choose Destination
Radiother Oncol. 2009 Jul;92(1):89-95. doi: 10.1016/j.radonc.2009.01.010. Epub 2009 Mar 28.

Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma.

Author information

1
Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, Osaka, Japan. msuzuki@rri.kyoto-u.ac.jp

Abstract

BACKGROUND AND PURPOSE:

To confirm the feasibility of accelerator-based BNCT (AB-BNCT) for treatment of multiple liver tumors and malignant pleural mesothelioma (MPM), we compared dose distribution and irradiation time between AB-BNCT and reactor-based BNCT (RB-BNCT).

MATERIAL AND METHODS:

We constructed treatment plans for AB-BNCT and RB-BNCT of four multiple liver tumors and six MPM. The neutron beam data on RB-BNCT were those from the research reactor at Kyoto University Research Reactor Institute (KURRI). The irradiation time and dose-volume histogram data were assessed for each BNCT system.

RESULTS:

In BNCT for multiple liver tumors, when the 5 Gy-Eq dose was delivered as the mean dose to the healthy liver tissues, the mean dose delivered to the liver tumors by AB-BNCT and RB-BNCT was 68.1 and 65.1 Gy-Eq, respectively. In BNCT for MPM, when the mean lung dose to the normal ipsilateral lung was 5 Gy-Eq, the mean dose delivered to the MPM tumor by AB-BNCT and RB-BNCT was 20.2 and 19.9 Gy-Eq, respectively. Dose distribution analysis revealed that AB-BNCT is superior to RB-BNCT for treatment of deep-seated tumors.

CONCLUSIONS:

The feasibility of the AB-BNCT system constructed at our institute was confirmed from a clinical viewpoint in BNCT for multiple liver tumors and MPM.

PMID:
19329206
DOI:
10.1016/j.radonc.2009.01.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center